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Abstract: Testicular germ cell tumors (TGCTs) derive from primordial germ cells. Their maturation
is blocked at different stages, reflecting histological tumor subtypes. A common genetic alteration
in TGCT is a deletion of the chromosome 1 short arm, where the PRDM2 gene, belonging to the
Positive Regulatory domain gene (PRDM) family, is located. Expression of PRDM2 gene is shifted in
different human tumors, where the expression of the two principal protein forms coded by PRDM2
gene, RIZ1 and RIZ2, is frequently unbalanced. Therefore, PRDM2 is actually considered a candidate
tumor suppressor gene in different types of cancer. Although recent studies have demonstrated that
PRDM gene family members have a pivotal role during the early stages of testicular development, no
information are actually available on the involvement of these genes in TGCTs. In this article we show
by qRT-PCR analysis that PRDM2 expression level is modulated by proliferation and differentiation
agents such as estradiol, whose exposure during fetal life is probably an important risk factor for
TGCTs development in adulthood. Furthermore in normal and cancer germ cell lines, PRDM2 binds
estradiol receptor α (ERα) and influences proliferation, survival and apoptosis, as previously reported
using MCF-7 breast cancer cell line, suggesting a potential tumor-suppressor role in TGCT formation.
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1. Introduction
Testicular germ cell tumors (TGCTs) are the most common malignant tumors in young males,
representing the major cause of cancer death in 15 to 34 years old males. Ninety-five percent of TGCTs
originate from germ cells and are classified into seminoma and non-seminoma germ cell tumors
(NSGCTs), including embryonic cell carcinoma, choriocarcinoma, yolk sac tumors and teratoma.
Tumors with diverse cell components, e.g., seminoma and embryonic cell carcinoma, are generally
indicated as mixed germ cell tumors. Seminomas and NSGCTs also show peculiar clinical features and
significant differences in therapy and prognosis [1–4].
In the last four decades, the incidence of TGCT doubled. Despite the efficacy of primary therapy,
the discovery of alternative adjuvant therapies aimed to limit relapses and prevent drug resistance
remains a priority. The molecular mechanisms underlying the onset, development and progression of
seminomas have not been explained yet. The genetic aberrations causing TGCT are complex; in fact,
the development of seminomas involves triploid/tetraploid chromosomes, short arm amplification of
chromosome 12, inducing CCND2 gene (cyclin D2) hyper-expression [5] and deletions of chromosomes
1, 3 or 11 short arms [4]. Whereas the etiology of TGCTs remains undefined, some authors described a
possible hormone-dependency of TGCT and formulated a hypothesis about a defect in the estrogen
signaling mechanism [6–9]. For example, in utero the exposure to particular hormones (e.g., estrogens)
during testis differentiation represents a risk factor for subsequent tumor development [10]. In addition,
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it was proposed that estrogen’s action on testicular cell transformation might involve oxidative DNA
damage mediated through estrogen receptors [11].
Estrogen signaling is exerted by two members of the nuclear receptors superfamily, estrogen
receptor α (ERα) and β (ERβ). They regulate transcription in a hormone-dependent manner.
These receptors, activated by estradiol binding, associate with other co-activators and repressors
and control the expression of target genes [12,13].
In the 1p chromosomal region, frequently deleted in TGCT, is located the PRDM2/RIZ gene [14,15],
suggesting a TGCT-suppressor role. The RIZ protein is involved in the alteration of the estrogen
transduction pathway through its hormone-dependent interaction with estrogen receptors [16–18].
Moreover, it localizes on estrogen-regulated gene promoters, acting as a co-activator when its
methyltransferase activity is inhibited by estradiol [16].
The human PRDM family gene contains 17 members that encode for proteins characterized
by a PR/SET domain and a different number of zinc-finger domains, aimed to regulate gene
expression [19–22]. Generally there are two alternative forms of PRDM proteins, PR plus (PR+)
forms and PR minus (PR−) forms, of which one differs from the other one only for the lack of the
PR domain. The PRDM2 gene encodes for two major proteins: RIZ1 (PR+) and RIZ2 (PR−) [23].
These two alternative products are involved in tumorigenesis with an unusual yin-yang manner.
A large number of human cancers, including breast, liver, bone, lung, colon, neuroendocrine cancers
and melanoma are characterized by the loss or the decreased expression of the PR+ form and a normal
or upregulated expression of PR− form [24–31]. RIZ gene deletion occurs also in colon, breast and liver
cancers [5,32,33]. No data are actually available about the expression and the role of PRDM-family
genes in TGCT. In particular, no evidence is available about PRDM2 gene, whose expression is altered
in a number of human hormone-dependent tumors [34]. Moreover, involvement of the PRDM2 gene
products in estrogen activity is still not well characterized in germinal cells.
To better clarify these aspects, we analyzed RIZ expression levels and its modulation by estrogens
using as a model the normal mouse spermatogonial GC-1 and the seminoma TCam-2 cell lines, because
both of them express RIZ proteins (RT-PCR analysis, densitometric analysis and Western blot analysis
are reported in Appendix Figure A1). Furthermore we studied the RIZ proteins potential role into the
mechanism responsible for tumorigenesis.
2. Materials and Methods
2.1. Cell Culture
GC-1 cell line from American Type Culture Collection (ATCC, Manassas, VA, USA) was
maintained in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 6% fetal bovine serum,
FBS (Invitrogen). TCam-2 cell line (kindly provided by Prof. L. H. Looijenga, Erasmus MC-University
Medical Center Rotterdam, Rotterdam, The Netherlands and P. Chieffi, University of Campania
“Luigi Vanvitelli”, Caserta, Italy) was cultured in RPMI 1640 (Invitrogen) containing 10% fetal calf
serum, FCS. Cell cultures were maintained in humidified 95% air and 5% CO2 atmosphere at 37 ◦C.
For treatments, 70% confluent cells were cultured in DMEM without phenol red and serum for one day
and subsequently treated for 24 hours with 100 nM 17β-estradiol (E2), 10 nM 5α-dihydrotestosterone
(DHT), 10 nM insulin-like growth factor (IGF-1) and 10 nM retinoic acid (RA) (Sigma-Aldrich Co.,
St. Louis, MO, USA).
2.2. Plasmid Transient Transfection
Plasmids carrying RIZ1 or RIZ2 coding sequences were obtained as previously described [35].
An empty vector (pSG5) was transfected in the control sample. Plasmid transfection was achieved
with Lipofectamine® reagent (GIBCO BRL, Life Technologies, Rockville, MD, USA) according to
manufacturer’s instructions. In each experiment, the plasmid pEGFPC3 was co-transfected to
detect and adapt the transfection efficiency by microscopy analysis. All presented data derive from
experiments with transfection efficiency greater than 55% and a variation below 20%.
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2.3. RNA Isolation and Quantitative Reverse-Transcription PCR (qRT-PCR) Analysis
Purification of GC-1 and TCam-2 cells total RNA (1 µg) was achieved with TRIzma Reagent
(Sigma-Aldrich Co.) following manufacturer’s instructions. RNA samples were eluted in 50 µL of
water treated with diethylpyrocarbonate and stored at−80 ◦C. The quality of RNA was assessed by gel
electrophoresis in denaturing conditions and by evaluation of 260/280 nm and 260/230 nm absorbance
ratios: RNA samples with absorbance ratio 260/280 nm lower than 1.9 or with absorbance ratio 260/230
lower than 2.2 were discarded. RNA samples were then treated with 40 U of RNAse-free DNAse-I
(Boehringer Mannheim, Indianapolis, IN, USA) for 45 minutes at 37 ◦C. To exclude the presence
of genomic DNA, PCR amplification was performed on RNA samples not reverse-transcribed, too.
MMLV-Reverse Transcriptase and random primers from Bio-Rad Laboratories Inc. (Hercules, CA, USA)
were used to reverse-transcribe total RNA.
cDNA aliquots were analyzed by qRT-PCR with the SYBR Green PCR Master Mix (Bio-Rad
Laboratories Inc., Hercules, CA, USA) in a Mastercycler ep Realplex (Eppendorf, Milan, Italy).
Relative mRNA expression was determined by the ∆∆-Ct method [36] using GAPDH mRNA
expression levels as endogenous control. Primer sets used are reported in Supplementary Material.
Serial cDNA dilutions were analyzed to ensure the linearity of the PCR reaction and to evaluate its
efficiency. cDNA samples were amplified in triplicate and the melting curves were analyzed to verify
the specificity of reaction.
2.4. Western Blot and Immunoprecipitation
Subconfluent GC-1 or TCam-2 cells were treated with 100 nM 17β-Estradiol (E2) (Sigma-Aldrich)
at different time intervals (0–5–15–30–60 minutes). Electrophoresis and Western blot analysis were
performed as described elsewhere [37] by using the rabbit polyclonal anti-RIZ antibodies (ab9710,
Abcam Ltd., Cambridge, UK) or the rabbit polyclonal anti-ERα antibodies (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). The same membrane was stripped and reprobed with the mouse
monoclonal anti-α-tubulin antibody (Sigma-Aldrich). For immunoprecipitation, 1 mg of total
protein cell lysate was incubated with 4 µg of rabbit polyclonal antibodies RIZ N-20 (Santa Cruz
Biotechnology Inc.) specific for RIZ. The clones of the antibodies used are reported in Supplementary
Material. Immunocomplexes were pulled down with anti-rabbit IgG beads (ExactaCruz, Santa Cruz
Biotechnology Inc.), according to the manufacturer’s instructions, and upon recovery subjected
to Western blot analysis. Densitometric analysis was performed with ImageJ software (ImageJ,
U.S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/) using the
“Gel Plot” plug-in.
2.5. Cell Growth Analysis
Cell proliferation was evaluated by cell counting and by MTT assay (Sigma-Aldrich Co.)
as previously indicated [38].
2.6. Clonogenic Assay
Clonogenic assay was performed as described elsewhere [39]. Transfected GC-1 cells (3 × 102)
expressing RIZ1, RIZ2 or empty vector (pSG5) were resuspended in DMEM, seeded into 6 well plates
and cultured for 15 days. Clones were fixed at room temperature with a solution containing 0.5%
crystal violet/6% glutaraldehyde (Sigma-Aldrich) for 30 minutes. Clones were counted with ImageJ
software using the “analyze particles” routine.
2.7. BrdU Incorporation Assay
DNA synthesis was assessed using the 5-Bromo-2′-deoxy-uridine labelling and detection kit
(Roche Applied Science, Penzberg, Germany), as previously described [38]. GC-1 cells were transfected
and after 24 hours, were plated in 96-well plates (4.0 × 103 cell/well) and cultured for an additional
24–48 hours; 10 µM BrdU (Roche Applied Science) was added in the last 4 hours and subsequently the
cell lysate was processed following the manufacturer’s instructions.
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2.8. TUNEL Assay
Apoptosis was assessed by APO-BrdU TUNEL assay detection kit, following manufacturer’s
instructions (Becton Dickinson, Franklin Lakes, NJ, USA). Cells were analyzed by flow cytometer
(FACS-CANTO II Becton–Dickinson).
2.9. Statistical Analysis
All data are presented as the means ± SD of at least three experiments in triplicates. Statistical
significance between groups was evaluated using Student’s t-test. All statistical analyses were
conducted using JMP Software purchased by Statistical Discovery SAS Institute (p < 0.05, statistical
significance; p < 0.001, high statistical significance).
3. Results
3.1. PRDM2 Expression Level is Modulated by Spermatogonial Proliferation and Differentiation Agents
Spermatogonial proliferation and differentiation agents modulation of PRDM2 gene transcription
was analyzed by qRT-PCR, using two sets of primers, PRDM2 PR and PRDM2 TOT, that recognize
sequences on the region coding PR domain of RIZ1 or on a region coding a sequence near the C-terminal
common to both RIZ1 and RIZ2, respectively [35]. In both GC-1 mouse spermatogonial normal cell line
and in TCam-2 human spermatogonial cancer cell line (Figure 1, panel A or B, respectively), treatment
with proliferation-inducing agents modulated the relative ratio between the major transcripts coded
by PRDM2 gene. In GC-1 cell line, E2 or IGF-1 treatment induced a significant increase of RIZ2
transcript. DHT treatment modulated positively both PRDM2 forms, as previously observed in EPN
cells (normal ephitelium prostate cell line) [34]. In both cell types, E2 increased the expression level
of the RIZ forms lacking the PR domain. In addition, in TCam-2 cells E2 reduced RIZ1 expression
levels. IGF-1 treatment increased expression levels of the RIZ forms lacking the PR domain in GC-1
cells. In conclusion, RIZ was still expressed in tumor phenotype and, according with previous results
obtained in MCF-7 breast cancer cell line, E2 modifies the RIZ1/RIZ2 ratio, lowering the expression
level of RIZ1 and raising the RIZ2 one [35,37]. E2 treatment also induces GC-1 [40] and TCam-2
proliferation (data not shown) [41] suggesting that the effect on cell growth is exerted by RIZ proteins.
Taken together, PRDM2 expression was maintained in cancer cell lines, suggesting that probably in
tumors the mechanism of action of RIZ proteins is modified.
3.2. In GC-1 and TCam-2 Cell Lines RIZ1 Binds ERα and This Interaction is Modulated by Estradiol Treatment
It has been previously demonstrated that RIZ1 binds ERα [16]. To investigate whether RIZ1 binds
ERα in normal GC-1 cell line and in TCam2 cancer cell line, following E2 treatment total protein extract
was immunoprecipitated with polyclonal anti-RIZ1 antibodies. Co-immunoprecipitated proteins
were pulled down and then processed and analyzed by SDS-PAGE followed by Western blot using
antibodies against RIZ or ERα proteins (Figure 2). In GC-1 cells RIZ1 was bound to ERα in basal
condition. The interaction raised after 15 minutes and peaked after 30 minutes of 100 nM E2 treatment
(Figure 2A). In TCam-2 cells RIZ1 was not co-immunoprecipitated with ERα in basal condition and the
interaction increased significantly only after 15 minutes of E2 treatment and declined after 60 minutes
(Figure 2B). The responsiveness to estradiol treatment was confirmed as control by the rapid increase
of ERK1/ERK2 phosphorylation (data not shown) [41].
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Figure 1. Modulation of PRDM2 gene expression by proliferation and differentiation agents. The 
transcripts encoded by PRDM2 gene was measured by qRT-PCR after a treatment with 100 nM E2, 10 
nM DHT, 10 nM retinoic acid (RA) or 10 nM insulin-like growth factor (IGF-1) for 48 hours. The 
PRDM2 PR and PRDM2 TOT sets of primers recognize sequences on the region coding PR domain of 
RIZ1 or on a region common to both RIZ1 and RIZ2 that encodes a sequence near the C-terminal end, 
respectively. The expression level is indicated as fold changes from basal conditions. Histograms 
represent the averages (+/− standard error) from at least three independent experiments, normalized 
for the expression of the control housekeeping gene GAPDH (# indicates p < 0.05 for RIZ1 or total RIZ, 
respectively, versus their untreated control). (A) qRT-PCR of total RNA/cDNA extracted from GC-1 
cell line; (B) qRT-PCR of mRNA/cDNA extracted from TCam-2 cell line. 
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vitro, colorimetric MTT assay was performed on GC-1 cells transiently transfected with the 
recombinant plasmids encoding for RIZ1 or RIZ2. pSG5 empty vector was used as control. Cells were 
harvested and analysed at time intervals of 0, 24 or 48 hours. Colorimetric MTT assay showed that 
RIZ1 over-expression inhibited cell proliferation, whereas RIZ2 over-expression had an increasing 
effect on it (Figure 3A). In addition, RIZ1 over-expression in GC-1 cells suppressed BrdU 
incorporation of about 20% compared to mock-transfected GC-1 cells. On the other hand RIZ2 over-
expression did not significantly suppress BrdU incorporation (Figure 3B). These results suggested 
that RIZ1 expression was required for DNA synthesis suppression, similar to the recent results 
obtained in a malignant meningioma cell line [42]. 
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Figure 2. RIZ1/ERα interaction. The interaction between RIZ1 and ERα was evaluated by 
immunoprecipitation, SDS-PAGE and Western blot analysis of total protein cell extracts from GC-1 
and TCam-2 cell lines treated with 100 nM estradiol (E2) for 5, 15, 30 or 60 minutes. 
Immunoprecipitation was performed with N-20 anti RIZ1 antibody; Western blot was performed 
with ab9710 anti-RIZ1, anti-ERα or anti-α-tubulin antibodies. An anti-rabbit IgG beads were used in 
the absence of N-20 anti RIZ1 antibody as a control (ctrl). Input: total protein cell extracts. ER/RIZ1 
binding graphs represent the ratio between the value obtained by densitometric analysis of the bands 
corresponding to ERα and RIZ1 by ImageJ software. The blots are representative of three independent 
experiments (# indicates p < 0.05). (A) GC-1 cell line; (B) TCam-2 cell line. 
3.4. RIZ1 Over-Expression Induces GC-1 Cells Apopotosis 
We investigated the influence of RIZ1 forced expression on apoptosis in GC-1 spermatogonial 
cell line. As shown in Figure 3C, RIZ1 over-expression significantly increased the number of GC-1 
apoptotic cells as compared with the control groups. 
Figure 2. RIZ1/ERα interaction. The interaction between RIZ1 and ERα was evaluated by
immunoprecipitation, SDS-PAGE and Western blot analysis of total protein cell extracts from GC-1 and
TCam-2 cell lines treated with 100 nM estradiol (E2) for 5, 15, 30 or 60 minutes. Immunoprecipitation
was performed with N-20 anti RIZ1 antibody; Western blot was performed with ab9710 anti-RIZ1,
anti-ERα or anti-α-tubulin antibodies. An anti-rabbit IgG beads were used in the absence of N-20
anti RIZ1 antibody as a control (ctrl). Input: total protein cell extracts. ER/RIZ1 binding graphs
represent the ratio between the value obtained by densitometric analysis of the bands corresponding
to ERα and RIZ1 by ImageJ software. The blots are representative of three independent experiments
(# indicates p < 0.05). (A) GC-1 cell line; (B) TCam-2 cell line.
3.4. RIZ1 Over-Expression Induces GC-1 Cells Apopotosis
We inve tigated the influence of RIZ1 forced expression on apoptosi in GC-1 spermatogonial
cell line. As shown in Figure 3C, RIZ1 over-expre sion significantly increased the number of GC-1
apoptotic cells as compared with the control groups.
Biology 2016, 5, 54 7 of 12Biology 2016, 5, 54 7 of 12 
 
 
Figure 3. Effect on cell proliferation, survival and apoptosis upon ectopic expression of RIZ1 or RIZ2 
in spermatogonial cell line GC-1. (A) For the colorimetric MTT assay, GC-1 cells transiently 
transfected with a plasmid encoding for RIZ1, RIZ2 or the empty vector (pSG5) were plated at the 
same density and allowed to grow for 0, 24 or 48 hours. MTT was added in the last 2 hours, formazan 
precipitates were dissolved with dimethyl sulfoxide reagent and absorbance read at 570 nm [38]. 
Values are the mean (±SE) of four analyses from three independent experiments # p < 0.05 vs. control; 
(B) For the BrdU incorporation assay, transiently transfected cells with a plasmid encoding for RIZ1, 
RIZ2 or for empty vector (pSG5) were seeded 24 hours after transfection into 96-well plates and 
cultured for further 24–48 hours; during the last 4 hours, cells were treated with 10 µM BrdU. The 
cells were processed following the manufacturer’s instructions and cell lysates were analyzed by an 
ELISA kit to measure the amount of incorporated BrdU with specific anti-BrdU antibody peroxidase-
conjugate. Data are represented as a percentage of basal values. Values are the mean (±SE) of four 
analyses from three independent experiments # p < 0.05 vs. control; (C) GC-1 cells, transiently 
transfected with a plasmid encoding for RIZ1, RIZ2 or with the control vector, were cultured in 60-
mm dishes for 24 or 48 hours. Cells were processed following manufacturer’s instruction and finally 
analyzed by flow cytometer to determine the percentage of apoptotic cells. The data are the mean of 
three independent experiments performed in triplicate (𝑛 = 9) # p < 0.05 vs. control. 
3.5. PRDM2 Influences Tumor Growth  
RIZ1 is silenced in different cancer cell lines and tumors, suggesting that RIZ1 acts as a tumor 
suppressor. Therefore, we evaluated the effects of ectopic RIZ1 expression on tumor cell 
clonogenicity. RIZ1 and RIZ2 encoding vectors (or the empty vector as control) were transfected into 
GC-1 cell line. Three hundred transfected cells were seeded in a 6-well plates and fifteen days later 
the count of the clones and the evaluation of their morphology by contrast microscopy was performed 
(Figure 4). Ectopic RIZ1 expression reduced the colony-forming efficiency, as compared to the vector 
control (40% and 50% respectively). Expression of RIZ1 or RIZ2 was confirmed by qRT-PCR and 
Western blot analysis [41]. 
Figure 3. Effect on cell proliferation, surviv l is upon ectopic expression of RIZ1 or RIZ2
in spermatogonial cell line GC-1. (A) For the colorimetric MTT assay, GC-1 cells transiently transfected
wi h a plasmid encoding for RIZ1, RIZ2 or the empty vector (pSG5) we e lated at the same density
and allowed to grow f r 0, 24 o 48 hours. MTT was added in the last 2 hours, formazan precipitates
were dissolved with dimethyl sulfoxide reagent and absorbance read at 570 nm [38]. Values are the
mean (±SE) of four analyses from three independent experiments # p < 0.05 vs. control; (B) For the
BrdU incorporation assay, transiently transfected cells with a plasmid encoding for RIZ1, RIZ2 or for
empty vector (pSG5) were seeded 24 hours after transfection into 96-well plates and cultured for further
24–48 hours; during the last 4 hours, cells were treated with 10 µM BrdU. The cells were processed
following the manufacturer’s instructions and cell lysates were analyzed by an ELISA kit to measure
the amount of incorporated BrdU with specific anti-BrdU antibody peroxidase-conjugate. Data are
represented as a percentage of basal values. Values are the mean (±SE) of four analyses from three
independent experiments # p < 0.05 vs. control; (C) GC-1 cells, transiently transfected with a plasmid
encoding for RIZ1, RIZ2 or with the control vector, were cultured in 60-mm dishes for 24 or 48 hours.
Cells were processed following manufacturer’s instruction and finally analyzed by flow cytometer to
determine the percentage of apoptotic cells. The data are the mean of three independent experiments
performed in triplicate (n = 9) # p < 0.05 vs. control.
3.5. PRDM2 Influences Tumor Growth
RIZ1 is silenced in different canc r cell lines and tumors, suggesting that RIZ1 acts as a tumor
suppressor. Therefore, we evaluated the effects of ectopic RIZ1 xp es io on tumor cell clonoge icity.
RIZ1 and RIZ2 encoding vectors (or the mpty vector as control) were transfecte into GC-1 cell line.
Thre h dred transfecte cells were seeded in a 6-we l plates a d fifteen days later the count of
the clones and the evaluation of their morphology by contrast microscopy was performed (Figure 4).
Ectopic RIZ1 expression reduced the colony-forming efficiency, as compared to the vector control
(40% and 50% respectively). Expression of RIZ1 or RIZ2 was confirmed by qRT-PCR and Western blot
analysis [41].
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Figure 4. Role of RIZ in GC-1 tumor growth. (A) GC-1 cells transiently transfected with indicated 
vectors, were seeded into 6-well plates. Fifteen days later the clones were fixed at room temperature 
with a solution containing 0.5% crystal violet/6% glutaraldehyde (Sigma-Aldrich) for 30 minutes. 
Clones were counted and their cellularity was evaluated by contrast microscopy; (B) The histograms 
represent the averages of colonies from four separate experiments performed in duplicate (  = 8). # p 
< 0.05 vs. control). 
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of RIZ2 transcript, suggesting a relative increment in RIZ2 expression over RIZ1 (Figure 1). 
Several reports suggested that RIZ1 is a downstream effector of estrogen action and that it is 
involved in regulation of cell proliferation in classical estrogen target tissues [16,18,35]. In our models, 
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estrogen control of cell growth through ERα. 
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motivation to characterize RIZ1 function in the molecular mechanisms underlying spermatogonial 
cell transformation. New insights, for example, could arise by using animal tumor models to evaluate 
the effect of RIZ1 on seminomas in vivo. 
Our data indicated also that RIZ1 over-expression induced apoptosis in GC-1 cells as pointed 
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Figure 4. Role of RIZ in GC-1 tumor growth. (A) GC-1 cells transiently transfected with indicated
vectors, were seeded into 6-well plates. Fifteen days later the clones were fixed at room temperature
with a solution containing 0.5% crystal violet/6% glutaraldehyde (Sigma-Aldrich) for 30 minutes.
Clones were counted and their cellularity was evaluated by contrast microscopy; (B) The histograms
represent the averages of colonies from four separate experiments performed in duplicate (n = 8).
# p < 0.05 vs. control.
4. Discussion
In this report we de onstrated that RIZ1 protein was expressed in spermatogonial-derived
cell lines. Consistent with previous results obtained in MCF-7 cell line [35,37], E2 treat ent of
spermatogonial cells induced a decrease in RIZ1 transcript expression level and a moderate increase of
RIZ2 transcript, suggesting a relative increment in RIZ2 expression over RIZ1 (Figure 1).
Several reports suggested that RIZ1 is a do nstrea effector of estrogen action and that it is
involved in regulation of cell proliferation in classical estrogen target tissues [16,18,35]. In our odels,
RIZ1 binding to ERα, potentiated by estradiol, strongly suggested a pivotal role for RIZ1 in ediating
estrogen control of cell growth through ERα.
Genetic data fro both ani al and hu an studies demonstrated that RIZ1 has a proven role
in cancer etiology. Fourteen different studies show a strong tumor-suppressive activity for RIZ1.
For example, in breast, liver and colon cancer RIZ1 over-expression causes G2-M cell cycle arrest
and/or apoptosis [43–45]. Moreover in many types of human tumors RIZ1 expression is deregulated.
o ever, the RIZ1 functional significance in se ino a develop ent has not been addressed yet.
e observed that, when ectopically expressed in GC-1 cells, RIZ1 suppressed the cell survival rate
and had a growth-inhibitory effect. These results clearly support the hypothesis that deregulation of
RIZ1 could have an essential role in sper atogonial cell transfor ation. ur data provide i portant
otivation to characterize RIZ1 function in the molecular mechanisms underlying spermatogonial cell
transformation. New insights, for example, could arise by using animal tumor odels to evaluate the
effect of RIZ1 on seminomas in vivo.
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Our data indicated also that RIZ1 over-expression induced apoptosis in GC-1 cells as pointed out
by the increase in the number of TUNEL-positive cells counted by flow cytometer. Previous reports
demonstrated that RIZ1 expression can induce p53 over-expression, and RIZ1 silencing limited p53
expression [42,46]. RIZ1 over-expression modifies antiapoptotic/apoptotic effectors, suggesting that
RIZ1 up-regulation could induce cell apoptosis and thus inhibit cell proliferation. Although the
mechanism underlying the association between RIZ1 expression and seminomas is still unclear, future
studies will focus on the identification of genomic alterations of PRDM2 gene, whose locus is on
chromosome 1p36, on the molecular mechanisms underlying PRDM2 gene expression modulation
and on the cell mechanisms associated with RIZ1 function. Our results strongly suggest that RIZ1 is
a promising candidate tumor-suppressor gene in the development of seminomas. We will attempt
to discover cell partners interacting with RIZ1 to elucidate how the deregulation of RIZ1 inhibits
cell growth.
5. Conclusions
Our findings support further characterization of molecular alterations in TGCT.
The understanding of the functional consequences of these alteration in deregulation of tumor
suppressor genes in TGCT cells will provide an important approach to discover new diagnostic and
therapeutic strategies.
Appendix A
Biology 2016, 5, 54 9 of 12 
 
reports demonstrated that RIZ1 expression can induce p53 over-expression, and RIZ1 silencing 
limited p53 expression [42,46]. RIZ1 over-expression modifies antiapoptotic/apoptotic effectors, 
suggesting that RIZ1 up-regulation could induce cell apoptosis and thus inhibit cell proliferation. 
Although the mechanism underlying the association between RIZ1 expression and seminomas is still 
unclear, future studies will focus on the identification of genomic alterations of PRDM2 gene, whose 
locus is on chromosome 1p36, on the molecular mechanisms underlying PRDM2 gene expression 
modulation and on the cell mechanisms associated with RIZ1 function. Our results strongly suggest 
that RIZ1 is a promising candidate tumor-suppressor gene in the development of seminomas. We 
will attempt to discover cell partners interacting with RIZ1 to elucidate how the deregulation of RIZ1 
inhibits cell growth.  
5. Conclusions 
Our findings support further characterization of molecular alterations in TGCT. The 
understanding of the functional consequences of these alteration in deregulation of tumor suppressor 




Figure A1. RIZ expression in GC-1 and TCam-2 cell lines. Western blot analyses of total protein cell 
extracts from GC-1 and TCam-2 cell lines with RIZ1 antibody. MCF-7 cell extract was used as a 
control. Electrophoresis analysis of amplicons obtained by RT-PCR of cDNA from GC-1 and TCam-2 
cells in basal condition (6% FBS DMEM for GC-1 cells and 10% FCS RPMI 1640 for TCam-2 cells). 
Densitometric analysis of the gels derived from three independent experiments, normalized for 
GAPDH signals. 
Supplementary Materials: The following are available online at www.mdpi.com/2079-7737/5/4/54/s1. 
Acknowledgements: This work was supported by grants from the Italian Ministry of University and Scientific 
Research PRIN. 
Author Contributions: Bruno Moncharmont contributed to the study design and supervised the experiments. 
Erika Di Zazzo performed cell cultures and treatments, qRT-PCR analysis, immunoprecipitation and western 
blot analysis, apoptosis analysis and clonogenic assays. Carola Porcile performed MTT and BrdU assays. Silvia 
Bartollino performed plasmids preparation and analysis. Erika Di Zazzo, Carola Porcile and Silvia Bartollino 
collaborated during experiments, performed data analysis and wrote the manuscript. 
Conflicts of Interest: The authors declare that they have no conflicts of interest. 
Abbreviations 
The following abbreviations are used in this manuscript: 
Figure A1. RIZ expression in GC-1 and TCam-2 cell lines. Western blot analyses of total protein cell
extracts from GC-1 and TCam-2 cell lines with RIZ1 antibody. MCF-7 cell extract was used as a control.
Electrophoresis analysis of amplicons obtained by RT-PCR of cDNA from GC-1 and TCam-2 cells in
basal condition (6% FBS DMEM for GC-1 cells and 10% FCS RPMI 1640 for TCam-2 cells). Densitometric
analysis of the gels derived from three independent experiments, normalized for GAPDH signals.
Supple entary aterials: The follo ing are available online at . dpi.co /2079-7737/5/4/54/s1.
Acknowledgments: This work was supported by grants from the Italian Ministry of University and Scientific
Research PRIN.
Author Contributions: Bruno Moncharmont contributed to the study design and supervised the experiments.
Erika Di Zazzo performed cell cultures and treatments, qRT-PCR analysis, immunoprecipitation and western
blot analysis, a opt sis analysis and clonogenic assays. Carola Porcile performed MTT and BrdU assays.
Silvia Bartollino performed plasmids preparation and analysis. Erika Di Zazzo, Carola Porcile and Silvia Bartollino
collaborated during experiments, performed data analysis and wrote the manuscript.
Conflicts of Interest: Th authors d cla e that they h ve no conflicts of interest.
Biology 2016, 5, 54 10 of 12
Abbreviations
The following abbreviations are used in this manuscript:
TGCTs Testicular germ cell tumors
NSGCTs non-seminoma germ cell tumors
ERα estrogen receptor α





SDS-PAGE Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis
References
1. Chieffi, P. Molecular targets for the treatment of testicular germ cell tumors. Mini Rev. Med. Chem. 2007, 7,
755–759. [CrossRef] [PubMed]
2. Chieffi, P. New prognostic markers and potential therapeutic targets in human testicular germ.
Curr. Med. Chem. 2011, 18, 5033–5040. [CrossRef] [PubMed]
3. Chieffi, P.; Franco, R.; Portella, G. Molecular and cell biology of testicular germ cell tumors. Int. Rev. Cell
Mol. Biol. 2009, 278, 277–308. [PubMed]
4. Oosterhuis, J.W.; Looijenga, L.H. Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer
2005, 5, 210–222. [CrossRef] [PubMed]
5. Houldsworth, J.; Reuter, V.; Bosl, G.J.; Chaganti, R.S. Aberrant expression of cyclin D2 is an early event in
human male germ cell tumorigenesis. Cell Growth Differ. 1997, 8, 293–299. [PubMed]
6. Lambard, S.; Carreau, S. Aromatase and oestrogens in human male germ cells. Int. J. Androl. 2005, 28,
254–259. [CrossRef] [PubMed]
7. Pais, V.; Leav, I.; Lau, K.M.; Jiang, Z.; Ho, S.M. Estrogen receptor-beta expression in human testicular germ
cell tumors. Clin. Cancer Res. 2003, 9, 4475–4482. [PubMed]
8. Rago, V.; Romeo, F.; Aquila, S.; Montanaro, D.; Ando, S.; Carpino, A. Cytochrome P450 aromatase expression
in human seminoma. Reprod. Biol. Endocrinol. 2005. [CrossRef] [PubMed]
9. Vicini, E.; Loiarro, M.; Di Agostino, S.; Corallini, S.; Capolunghi, F.; Carsetti, R.; Chieffi, P.; Geremia, R.;
Stefanini, M.; Sette, C. 17-beta-estradiol elicits genomic and non-genomic responses in mouse male germ
cells. J. Cell. Physiol. 2006, 206, 238–245. [CrossRef] [PubMed]
10. Henderson, B.E.; Benton, B.; Jing, J.; Yu, M.C.; Pike, M.C. Risk factors for cancer of the testis in young men.
Int. J. Cancer 1979, 23, 598–602. [CrossRef] [PubMed]
11. Wellejus, A.; Loft, S. Receptor-mediated ethinylestradiol-induced oxidative DNA damage in rat testicular.
FASEB J. 2002, 16, 195–201. [CrossRef] [PubMed]
12. Katzenellenbogen, B.S.; Montano, M.M.; Ediger, T.R.; Sun, J.; Ekena, K.; Lazennec, G.; Martini, P.G.;
McInerney, E.M.; Delage-Mourroux, R.; Weis, K.; et al. Estrogen receptors: Selective ligands, partners,
and distinctive pharmacology. Recent Prog. Horm. Res. 2000, 55, 163–193. [PubMed]
13. Pettersson, K.; Gustafsson, J.A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 2001, 63,
165–192. [CrossRef] [PubMed]
14. Buyse, I.M.; Shao, G.; Huang, S. The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares
an epitope with the adenovirus E1A protein. Proc. Natl. Acad. Sci. USA 1995, 92, 4467–4471. [CrossRef]
[PubMed]
15. Huang, S. The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Front. Biosci.
1999, 4, 528–532. [CrossRef]
16. Abbondanza, C.; Medici, N.; Nigro, V.; Rossi, V.; Gallo, L.; Piluso, G.; Belsito, A.; Roscigno, A.; Bontempo, P.;
Puca, A.A.; et al. The retinoblastoma-interacting zinc-finger protein RIZ is a downstream effector of estrogen
action. Proc. Natl. Acad. Sci. USA 2000, 97, 3130–3135. [CrossRef] [PubMed]
17. Carling, T.; Kim, K.C.; Yang, X.H.; Gu, J.; Zhang, X.K.; Huang, S. A Histone Methyltransferase Is Required
for Maximal Response to Female Sex Hormones. Mol. Cell. Biol. 2004, 24, 7032–7042. [CrossRef] [PubMed]
Biology 2016, 5, 54 11 of 12
18. Medici, N.; Abbondanza, C.; Nigro, V.; Rossi, V.; Piluso, G.; Belsito, A.; Gallo, L.; Roscigno, A.; Bontempo, P.;
Puca, A.A.; et al. Identification of a DNA binding protein cooperating with estrogen receptor as RIZ
(retinoblastoma interacting zinc finger protein). Biochem. Biophys. Res. Commun. 1999, 264, 983–989.
[CrossRef] [PubMed]
19. Ancelin, K.; Lange, U.C.; Hajkova, P.; Schneider, R.; Bannister, A.J.; Kouzarides, T.; Surani, M.A.
Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat. Cell Biol.
2006, 8, 623–630. [CrossRef] [PubMed]
20. Davis, C.A.; Haberland, M.; Arnold, M.A.; Sutherland, L.B.; McDonald, O.G.; Richardson, J.A.; Childs, G.;
Harris, S.; Owens, G.K.; Olson, E.N. PRISM/PRDM6, a Transcriptional Repressor That Promotes the
Proliferative Gene Program in Smooth Muscle Cells. Mol. Cell. Biol. 2006, 26, 2626–2636. [CrossRef]
[PubMed]
21. Di Zazzo, E.; De Rosa, C.; Abbondanza, C.; Moncharmont, B. PRDM Proteins: Molecular Mechanisms in
Signal Transduction and Transcriptional Regulation. Biology 2013, 2, 107–141. [CrossRef] [PubMed]
22. Hayashi, K.; Yoshida, K.; Matsui, Y. A histone H3 methyltransferase controls epigenetic events required for
meiotic prophase. Nature 2005, 438, 374–378. [CrossRef] [PubMed]
23. Liu, L.; Shao, G.; Steele-Perkins, G.; Huang, S. The retinoblastoma interacting zinc finger gene RIZ produces
a PR domain-lacking product through an internal promoter. J. Biol. Chem. 1997, 272, 2984–2991. [CrossRef]
[PubMed]
24. Geli, J.; Kiss, N.; Kogner, P.; Larsson, C. Suppression of RIZ in biologically unfavourable neuroblastomas.
Int. J. Oncol. 2010, 37, 1323–1330. [CrossRef] [PubMed]
25. Geli, J.; Nord, B.; Frisk, T.; Edstrom Elder, E.; Ekstrom, T.J.; Carling, T.; Backdahl, M.; Larsson, C. Deletions
and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal
paragangliomas. Int. J. Oncol. 2005, 26, 1385–1391. [CrossRef] [PubMed]
26. Piao, Z.; Fang, W.; Malkhosyan, S.; Kim, H.; Horii, A.; Perucho, M.; Huang, S. Frequent frameshift mutations
of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability. Cancer Res.
2000, 60, 4701–4704. [PubMed]
27. Poetsch, M.; Dittberner, T.; Woenckhaus, C. Frameshift mutations of RIZ, but no point mutations in RIZ1
exons in malignant melanomas with deletions in 1p36. Oncogene 2002, 21, 3038–3042. [CrossRef] [PubMed]
28. Sakurada, K.T.; Furukawa, T.; Kato, Y.; Kayama, T.; Huang, S.; Horii, A. RIZ, the retinoblastoma protein
interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and
colorectum. Genes Chromosomes Cancer 2001, 30, 207–211. [CrossRef]
29. Sasaki, O.; Meguro, K.; Tohmiya, Y.; Funato, T.; Shibahara, S.; Sasaki, T. Altered expression of retinoblastoma
protein-interacting zinc finger gene, RIZ, in human leukaemia. Br. J. Haematol. 2002, 119, 940–948. [CrossRef]
[PubMed]
30. Steele-Perkins, G.; Fang, W.; Yang, X.H.; van Gele, M.; Carling, T.; Gu, J.; Buyse, I.M.; Fletcher, J.A.;
Liu, J.; Bronson, R.; et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear
protein-methyltransferase superfamily. Genes Dev. 2001, 15, 2250–2262. [CrossRef] [PubMed]
31. Mzoughi, S.; Tan, Y.X.; Low, D.; Guccione, E. The role of PRDMs in cancer: One family, two sides. Curr. Opin.
Genet. Dev. 2016, 36, 83–91. [CrossRef] [PubMed]
32. Chadwick, R.B.; Jiang, G.L.; Bennington, G.A.; Yuan, B.; Johnson, C.K.; Stevens, M.W.; Niemann, T.H.;
Peltomaki, P.; Huang, S.; de la Chapelle, A. Candidate tumor suppressor RIZ is frequently involved in
colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA 2000, 97, 2662–2667. [CrossRef] [PubMed]
33. Fang, W.; Piao, Z.; Buyse, I.M.; Simon, D.; Sheu, J.C.; Perucho, M.; Huang, S. Preferential loss of a polymorphic
RIZ allele in human hepatocellular carcinoma. Br. J. Cancer 2001, 84, 743–747. [CrossRef] [PubMed]
34. Rossi, V.; Staibano, S.; Pasquali, D.; de Rosa, C.; Mascolo, M.; Bellastella, G.; Visconti, D.; de Bellis, A.;
Moncharmont, B.; de Rosa, G.; et al. Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger
protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro
by DHT and E2. J. Cell. Physiol. 2009, 221, 771–777. [CrossRef] [PubMed]
35. Gazzerro, P.; Abbondanza, C.; D’Arcangelo, A.; Rossi, M.; Medici, N.; Moncharmont, B.; Puca, G.A.
Modulation of RIZ gene expression is associated to estradiol control of MCF-7 breast cancer cell proliferation.
Exp. Cell Res. 2006, 312, 340–349. [CrossRef] [PubMed]
36. Pfaffl, M.W. Relative quantification. In Real Time PCR BIOS Advanced Methods; Dorak, T., Ed.; Taylor & Francis:
Abingdon, UK, 2006; Volume 16, pp. 63–82.
Biology 2016, 5, 54 12 of 12
37. Abbondanza, C.; de Rosa, C.; D’Arcangelo, A.; Pacifico, M.; Spizuoco, C.; Piluso, G.; di Zazzo, E.; Gazzerro, P.;
Medici, N.; Moncharmont, B.; et al. Identification of a functional estrogen-responsive enhancer element in
the promoter 2 of PRDM2 gene in breast cancer cell lines. J. Cell. Physiol. 2012, 227, 964–975. [CrossRef]
[PubMed]
38. Porcile, C.; Di Zazzo, E.; Monaco, M.L.; D’Angelo, G.; Passarella, D.; Russo, C.; Di Costanzo, A.; Pattarozzi, A.;
Gatti, M.; Bajetto, A.; et al. Adiponectin as novel regulator of cell proliferation in human glioblastoma.
J. Cell. Physiol. 2014, 229, 1444–1454. [CrossRef] [PubMed]
39. Di Zazzo, E.; Feola, A.; Zuchegna, C.; Romano, A.; Donini, C.F.; Bartollino, S.; Costagliola, C.; Frunzio, R.;
Laccetti, P.; Di Domenico, M.; et al. The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin
biological effects on MCF-7 cell growth and motility. Sci. World J. 2014. [CrossRef] [PubMed]
40. Sirianni, R.; Chimento, A.; Ruggiero, C.; De Luca, A.; Lappano, R.; Andò, S.; Maggiolini, M.; Pezzi, V.
The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by
17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology 2008, 149, 5043–5051. [CrossRef]
[PubMed]
41. Di Zazzo, E.; Department of Health Sciences, University of Molise, Campobasso, Italy. Unpublished results. 2014.
42. Liu, Z.Y.; Wang, J.Y.; Liu, H.H.; Ma, X.M.; Wang, C.L.; Zhang, X.P.; Tao, Y.Q.; Lu, Y.C.; Liao, J.C.;
Hu, G.H.; et al. Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human
malignant meningiomas. Oncogene 2013, 32, 1216–1222. [CrossRef] [PubMed]
43. He, L.; Yu, J.X.; Liu, L.; Buyse, I.M.; Wang, M.S.; Yang, Q.C.; Nakagawara, A.; Brodeur, G.M.; Shi, Y.E.;
Huang, S. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer,
and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 1998, 58, 4238–4244.
[PubMed]
44. Jiang, G.; Liu, L.; Buyse, I.M.; Simon, D.; Huang, S. Decreased RIZ1 expression but not RIZ2 in hepatoma
and suppression of hepatoma tumorigenicity by RIZ1. Int. J. Cancer 1999, 83, 541–546. [CrossRef]
45. Jiang, G.L.; Huang, S. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of
microsatellite-unstable colorectal cancers. Cancer Res. 2001, 61, 1796–1798. [PubMed]
46. Shadat, N.M.; Koide, N.; Khuda, I.I.; Dagvadorj, J.; Tumurkhuu, G.; Naiki, Y.; Komatsu, T.; Yoshida, T.;
Yokochi, T. Retinoblastoma protein interacting zinc finger 1 (RIZ1) regulates the proliferation of monocytic
leukemia cells via activation of p53. Cancer Investig. 2010, 28, 806–812. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
